- Home
- SPRY vs ADPT Comparison
SPRY vs ADPT Comparison
Compare SPRY & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRY
- ADPT
- Stock Information
- Founded
- SPRY 2015
- ADPT 2009
- Country
- SPRY United States
- ADPT United States
- Employees
- SPRY 24
- ADPT N/A
- Industry
- SPRY Biotechnology: Pharmaceutical Preparations
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SPRY Health Care
- ADPT Health Care
- Exchange
- SPRY Nasdaq
- ADPT Nasdaq
- Market Cap
- SPRY 1.2B
- ADPT 1.2B
- IPO Year
- SPRY N/A
- ADPT 2019
- Fundamental
- Price
- SPRY $11.95
- ADPT $7.17
- Analyst Decision
- SPRY Strong Buy
- ADPT Buy
- Analyst Count
- SPRY 5
- ADPT 5
- Target Price
- SPRY $26.80
- ADPT $9.10
- AVG Volume (30 Days)
- SPRY 1.3M
- ADPT 1.9M
- Earning Date
- SPRY 03-20-2025
- ADPT 05-06-2025
- Dividend Yield
- SPRY N/A
- ADPT N/A
- EPS Growth
- SPRY N/A
- ADPT N/A
- EPS
- SPRY N/A
- ADPT N/A
- Revenue
- SPRY $2,568,000.00
- ADPT $178,957,000.00
- Revenue This Year
- SPRY $61,233.33
- ADPT $21.21
- Revenue Next Year
- SPRY $585.54
- ADPT $21.98
- P/E Ratio
- SPRY N/A
- ADPT N/A
- Revenue Growth
- SPRY 8460.00
- ADPT 5.10
- 52 Week Low
- SPRY $7.55
- ADPT $2.28
- 52 Week High
- SPRY $18.51
- ADPT $8.95
- Technical
- Relative Strength Index (RSI)
- SPRY 55.76
- ADPT 42.16
- Support Level
- SPRY $10.00
- ADPT $6.26
- Resistance Level
- SPRY $11.55
- ADPT $7.89
- Average True Range (ATR)
- SPRY 0.69
- ADPT 0.75
- MACD
- SPRY 0.21
- ADPT -0.15
- Stochastic Oscillator
- SPRY 78.00
- ADPT 34.08
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).